Medical Device Due Diligence by a Physician-Engineer Team

We assess what financial DD can't: clinical adoption, manufacturing scalability, regulatory viability, and reimbursement pathways. Vantage is the only medtech DD firm led by an MD and a biomedical engineer — combining clinical insight with technical rigor.

Schedule Consultation See Our Process How It Works

MedTech Startup Failure Rate_†1

2-3 wk

Typical Turnaround_†2

MD + BME

Dual Expertise

Senior Advisor: Rinda Sama — CEO, Spiro Medical | Former COO, Axonics ($4.1B BSX acquisition) | Board, UroMems | BME (USC) + MBA (UCI)

The Vantage Difference

Why Clinical and Engineering Expertise Matter

Standard due diligence evaluates financials, legal, and market sizing. It wasn't designed to assess whether physicians will adopt a device, whether it can be manufactured under FDA QSR, or whether a reimbursement pathway exists. That requires clinical and engineering expertise.

Vantage is the only medtech DD firm led by an MD and a biomedical engineer — combining clinical insight with technical rigor.

Who We Serve

Five Audiences, Five Different Hooks

For PE Healthcare

Portfolio-level risk scoring across platform and bolt-on acquisitions. Know which companies in your pipeline face adoption headwinds.

96% historical risk classification accuracy across 100+ companies

Explore Services

For Strategic Acquirers

Clinical-technical DD that fits your M&A timeline. Compressed assessment windows without compromising rigor.

2-4 week turnaround — built for M&A deal timelines

Explore Services

For Investors & VCs

Pre-investment assessment before the wire transfer. Identify adoption risk, manufacturing viability, and regulatory clear-eyed view.

75% of assessed companies had risks standard DD missed

Explore Services

For Founders

Know where you stand before investors ask. Stress-test your story against clinical, regulatory, and manufacturing realities.

Vantage Score: quantified readiness for investor conversations

Explore Services

For Universities & TTOs

Prioritize your portfolio by commercial viability. Identify which projects deserve scaled-up investment vs. early pivot.

Standardized risk scoring for portfolio-wide visibility

Explore Services

Our Assessment Framework

Every Vantage engagement includes integrated clinical, regulatory, engineering, and commercial analysis — delivered by our MD + BME team.

Integrated Analysis

Proprietary scoring across all dimensions — clinical, regulatory, engineering, commercial. No siloed opinions.

Pattern Intelligence

Matched against our documented outcomes. Your report leverages our entire risk database.

Score Portability

Your reports are yours to use — pitch decks, IC memos, data rooms. No fees. No restrictions.

Explore our methodology in detail

Our Value Proposition

Integrated Assessment vs. Fragmented Approach

Most firms piece together three separate consultants. Vantage delivers integrated analysis — clinical, regulatory, engineering, and commercial — in one assessment, faster and more cost-effective.

Approach	Cost	Timeline	Scope	Vantage Equivalent
Regulatory Consultant	$15K–$50K	2–4 weeks	Regulatory pathway only — no commercial, manufacturing, or clinical adoption analysis	Included in every Vantage assessment as part of Domain A (4 categories)
Manufacturing Advisor	$20K–$40K	2–3 weeks	Manufacturing feasibility only — no regulatory or market fit analysis	Included as part of Domain B — assessed by BME with engineering depth
Clinical KOL / Advisor	$15K–$25K	Varies	Clinical opinion only — no structured scoring or pattern matching	Included as Domain A + D — assessed by MD with clinical depth
All Three Combined	$50–100K+	6–8 weeks	No integration between assessments. You synthesize the findings yourself.	Starting at $5,000 — fully integrated, 2–3 weeks_†3

Industry rate sources: OMC Medical Fee Schedule · NIH SEED Consulting Guide · Qualio · MedEnvoy

Our Layered Approach

Four Dimensions of Risk Assessment

Our MD + BME analysis spans regulatory, clinical, engineering, and commercial dimensions—each layer revealing risks that point-focused review cannot address.

Complete Assessment Spans Four Dimensions

Clinical, regulatory, engineering, and commercial analysis together. This integrated approach reveals risk patterns that domain-specific assessments miss.

See Our Full Process

01Surface

Standard Due DiligenceMBA / Finance / Legal

✓ Pitch deck ✓ Financials ✓ Team bios ✓ Market size ✓ Cap table

All clear

02Clinical

Clinical AnalysisPhysician (MD) — CMO

✓ Clinical validity ! Trial endpoints ! Workflow fit ✓ Patient safety ! Adoption path

3 risks

03Eng

Engineering AnalysisBiomedical Engineer (BME)

! IP landscape ! BOM / unit cost ! Mfg scalability ✓ Tech feasibility ! Reg pathway

4 risks

04Deep

Converged FindingsMD + BME Consensus

✗ 510(k) pathway blocked ✗ Unit economics fatal ! 3-year delay risk

2 critical

Clear

Risk found

Critical

How We Compare

Vantage vs. Alternatives

All-in-one integrated assessment beats assembling separate specialists.

Capability	Assembling 3+ Specialists	Regulatory-Only Advisors	Clinical Advisors	Vantage
Cost	$50-100K+	$20-30K	$10-15K	$4-45K
Turnaround Time	4-8 weeks combined	2-4 weeks	Varies	2-3 weeks
Assessment Scope	Depends on who you hire	FDA pathway only	Clinical opinion only	All proprietary categories
Medical Device Expertise	Siloed perspectives	Tunnel vision on FDA	No systematic scoring	Proprietary Pattern Database

The Bottom Line: What separately costs $50-100K+ and takes 6-8 weeks, Vantage delivers integrated in 2-3 weeks.

How It Works

From Submission to Strategic Insight

Your assessment moves through six integrated stages — each combining physician expertise with engineering rigor.

Step 1 of 6

Submit

Upload your materials

Clinical Review

Physician analysis

Technical Review

Engineering analysis

Pattern Match

proprietary database

Risk Scoring

proprietary Vantage Score

Report Delivery

Actionable intelligence

Secure Document Upload

You provide company materials through our encrypted portal. We handle the rest. Typical uploads include pitch deck, regulatory filings, clinical data, financial projections, and competitive analysis.

Pitch deck & investor materials

FDA submissions & regulatory files

Clinical trial data & publications

Financial projections & cap table

Patent portfolio & IP filings

Manufacturing & quality docs

Physician Clinical Analysis

Our physician reviews from the clinical lens — the perspective VCs and consultants cannot replicate. This catches the adoption barriers that kill 75% of medical device startups.

Clinical adoption feasibility

Evidence & outcomes evaluation

Safety profile assessment

Competitive landscape analysis

Biomedical Engineering Review

Our BME assesses technical feasibility, manufacturing scalability, regulatory pathway, and IP strength — the engineering depth that separates real risk from surface-level DD.

Regulatory pathway assessment

Manufacturing & scalability review

IP strength evaluation

Design & quality analysis

Pattern Intelligence Engine

Your company's risk profile is cross-referenced against our proprietary database of documented medtech outcomes — spanning multiple device specialties — to surface patterns standard due diligence cannot detect.

Proprietary outcome database spanning multiple specialties

Failure pattern recognition across device categories

Success benchmarking against comparable exits

Cross-domain risk signal correlation

Historical precedent identification

96% historical accuracy_†4

Proprietary Vantage Score

Each assessment produces a composite Vantage Score — a single, calibrated metric that synthesizes risk across all four domains. The score distinguishes between risks that require immediate intervention and those manageable with the right roadmap.

Composite score across four assessment domains

Domain-level risk breakdown with justification

Terminal vs. remediable risk classification

Calibrated against documented outcomes

Stage-weighted scoring (seed through growth)

Prioritized remediation roadmap

Your Deliverable

A comprehensive report with executive summary, full proprietary scoring, risk analysis with historical precedents, remediation roadmap, and a 1-hour findings call with your team.

Executive Summary

Scoring Matrix

Remediation Plan

2-3 weeks

Our Team

The MD + BME Partnership

Two perspectives, one mission: protecting your investment with insight that matters.

Founded by Dr. Arvind Ravinutala (MD) and Aswini Ravinutala (BS BME, UC Irvine; MSE Quality & Reliability, ASU; ex-Axonics) — with C-suite advisory from Rinda Sama and a physician specialist network spanning 8 device categories. Meet the full team →

Arvind Ravinutala, MD

Chief Medical Officer

Clinical Informatics • Bioethics

Practicing physician and Medical Director at Adventist Health White Memorial. Chairs P&T Committee evaluating device adoption for 150+ physicians.

Connect

Aswini Ravinutala, MSE

Chief Technology Officer

Axonics (→ $4.1B BSX Acquisition)

Operations engineering at Axonics through Boston Scientific's $4.1B acquisition. Assesses manufacturing scalability, quality systems, and engineering team depth.

Connect

Common Questions

Frequently Asked

Founder Readiness Screen starting at $5,000. Full Vantage Assessment from $10,000 (founders) to $30,000 (investor due diligence). Annual retainers available for institutional partners. All assessments include integrated MD + BME analysis and pattern-matching against our validated database.

Standard turnaround is 2–3 weeks. Our rapid assessment option delivers in 5 business days for competitive deal situations. We work on your timeline—not ours.

A comprehensive report (30–70 pages depending on tier) that includes an executive summary, proprietary scoring matrix, physician and engineer perspectives, risk analysis with historical precedents, 50+ follow-up diligence questions, and a clear invest/pass recommendation. We also deliver a 1-hour findings call with your team.

Two things: clinical depth and speed. Our physician sits on hospital P&T committees and evaluates device adoption daily. Our engineer built devices at Boston Scientific and Axonics. Traditional consultants rely on desk research and interviews—we bring pattern recognition from real clinical and manufacturing experience. We combine clinical, regulatory, engineering, and commercial analysis in one integrated engagement — delivered in 2-3 weeks.

Yes. Our Founder Certification program is designed specifically for pre-revenue medical device companies preparing to raise. We assess your regulatory pathway, clinical positioning, and investor readiness—helping you identify and address gaps before VCs find them. It's also affordable enough to fund through SBIR Phase I grants.

Your initial assessment establishes a permanent baseline in our system. Return engagements — after a pivot, milestone, or gap remediation — are 40% off because the analytical foundation is already built. Your Vantage Score reports are yours to share freely in pitch decks, data rooms, and board materials. We also offer quarterly advisory, referral credits, and portfolio-level tracking for institutional clients.

Your Assessment Gets Smarter Over Time

Built-In Compounding Value

Every Vantage engagement draws on a growing pattern database — so the assessment you receive today is sharper than the one we could have delivered six months ago.

Deeper Pattern Matching

Each engagement adds real-world outcome data to our proprietary scoring methodology — surfacing regulatory and commercial patterns specific to your device category

Faster Turnaround

More data per category means faster identification of predicate risks, reclassification traps, and reimbursement blind spots — you get answers sooner

Return Engagements Cost Less

Re-assessments and portfolio follow-ups are priced at 40% off because your baseline is already in the system — no redundant work

Built for repeat engagement: Every assessment you commission makes the next one faster, sharper, and more category-specific — and return engagements are priced accordingly.

Have questions? See our FAQ → | Try our free assessment tools →

Free Download

10 Red Flags That Predict Medical Device Failure

10 patterns that predict medical device failure — identified through our analysis. Free checklist for VCs and founders.

Download the Free Guide

What's Inside

✓ The 10 failure patterns with real data
✓ Correlation scores for each red flag
✓ Quick-screen checklist for any device
✓ Case examples from our proprietary database

No spam. Just the guide. Unsubscribe anytime.

Research Sources & Citations

†1 - 75% of Medical Device Startups Fail: Analysis based on FDA 510(k) clearance data and venture capital outcomes across device categories (2020-2024). See methodology at vantagebiomed.com/methodology.
†2 - 2-3 Week Turnaround: Standard assessment timeline assuming complete information submission. Expedited assessments available for time-sensitive transactions.
†3 - Comparison Data ($50-100K for Traditional Consultants): Based on published rate schedules from major biomedical consulting firms and industry surveys (2025). Sources: OMC Medical, NIH SEED Consulting Guide, Qualio, MedEnvoy.
†4 - 96% Historical Accuracy: Retrospective validation of Vantage scoring framework against documented medical device outcomes across 100+ companies.

For detailed methodology and data sources, visit our Methodology & Research page.

Medical Device Due Diligence by a Physician-Engineer Team

Why Clinical and Engineering Expertise Matter

Five Audiences, Five Different Hooks

For PE Healthcare

For Strategic Acquirers

For Investors & VCs

For Founders

For Universities & TTOs

Our Assessment Framework

Integrated Analysis

Pattern Intelligence

Score Portability

Integrated Assessment vs. Fragmented Approach

Four Dimensions of Risk Assessment

Complete Assessment Spans Four Dimensions

Vantage vs. Alternatives

From Submission to Strategic Insight

The MD + BME Partnership

Arvind Ravinutala, MD

Aswini Ravinutala, MSE

Frequently Asked

Built-In Compounding Value

Deeper Pattern Matching

Faster Turnaround

Return Engagements Cost Less

Breadth of Due Diligence

The Medical Device M&A Landscape: 2025 in Review and 2026 Outlook

The Predicate Trap: When Your 510(k) Strategy Backfires

Anatomy of a Failed Device Launch

10 Red Flags That Predict Medical Device Failure

Ready to De-Risk Your Next Investment?